mental health – Talk Bio

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

4 days ago talkbio0Tagged Clearmind Medicine, Clinical Trials, governmental engagement, Mary-Elizabeth, mental health, partnerships, psychedelic medicine, regulatory advocacy, U.S.

Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

2 months ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

CDC Launches ‘Free Mind’ Campaign Targeting Teen Substance Use and Mental Health

3 months ago talkbio0Tagged Adolescence, Alcohol or Other Drugs use, Centers for Disease Control and Prevention (U.S.), Drug Overdose, fentanyl, Free Mind ' Campaign, mental health, Strategy, teen suicide

CDC; Free Mind campaign; youth mental health; substance use; drug overdose; fentanyl; teen suicide; coping strategies

Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments

9 months ago talkbio0Tagged Anxiety Disorders, assets, Funding, GABA Modulators, mental health, Neuropsychiatry, Newleos, Roche (company), Series, Substance Use Disorders

Newleos Therapeutics, mental health, neuropsychiatry, Roche assets, Series A funding, anxiety disorders, substance use disorders, GABA modulators

Negev Labs Unveils Next-Gen Psychedelic Therapies with Non-Hallucinogenic Neuroplastogens

11 months ago talkbio0Tagged Biotechnology, Builder, Hallucinogens, Laboratory test finding, mental health, Negev, neuroplastogens, non-hallucinogenic, psychedelic therapies

Negev Labs, neuroplastogens, psychedelic therapies, non-hallucinogenic psychedelics, mental health treatments, biotechnology company builder

Cybin’s Psychedelic Breakthroughs: Advancing Mental Health Treatments

12 months ago talkbio0Tagged Breakthrough Therapy, Clinical Trials, Cybin, Hallucinogens, Identifier, mental health, N,N-Dimethyltryptamine, Psilocybin, United States Food and Drug Administration

Cybin, psychedelic therapeutics, mental health treatments, deuterated psilocybin, deuterated DMT, clinical trials, FDA Breakthrough Therapy Designation.

Semaglutide and Mental Health: A Complex Relationship

1 year ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, ideation, mental health, semaglutide, Suicidal

semaglutide, mental health, suicidal ideation, GLP-1 drugs, weight loss, diabetes

Rapport Neuroscience Biotech Aims for Expansion with Initial Public Offering

1 year ago talkbio0Tagged clinical-stage, expansion, IPO, mental health, nervous system disorder, Neuroscience discipline, Rapport

Rapport, neuroscience, biotech, IPO, clinical-stage, expansion, pharmaceuticals, neurological disorders, mental health

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

1 year ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.

Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment

1 year ago talkbio0Tagged Collaboration, Injectables, long-acting, Medincell, mental health, Neuroscience discipline, Phase 3 trials, Psychiatry Specialty, Schizophrenia, Teva, Uzedy

Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.